|
|
Post by babaoriley on Jul 2, 2014 9:44:59 GMT -5
So friggin typical, even my hair hurts. Downgrades and nasty articles aplenty. For those who don't have their fill and have a few bucks, not a bad deal.
|
|
|
|
Post by mdcenter61 on Jul 2, 2014 9:59:59 GMT -5
So friggin typical, even my hair hurts. Downgrades and nasty articles aplenty. For those who don't have their fill and have a few bucks, not a bad deal. I feel your pain.....bought more Leaps yesterday with what little dry powder I had left. Have my own little fantasy that Al announces partnership after hours tomorrow so that shorts can have a miserable long weekend! I ain't selling....this is miserable to watch but this is how the Street operates with a gutless castrated SEC. |
|
|
|
Post by bradleysbest on Jul 2, 2014 10:15:12 GMT -5
I must admit my confidence is shaken a bit by the stock drop. Simply put I expected FDA approval to really get the ball rolling for us. Not only in a price jump (14-15 pps) but I expected the "band wagon" investors to jump aboard. The negative articles are still coming with full guns blazing! I am long but am hopeful the "partnership" will be the key for us who believe in the product as well as want to make a few dollars. Partnership plus a good marketing strategy should be the key for us!
|
|
|
|
Post by mannmade on Jul 2, 2014 10:18:37 GMT -5
Baba, good thing we both don't have as much hair as we used too...  But this shall pass... None of the articles can say much about the science. Just the label. And Afrezza's HUGE benefits will be proved out as time goes by... Just as the negative jive talk will fade away as it is proved to be mostly untrue or statistically insignificant... As investors our timeline may be derailed a bit but for diabetics theirs has been given new speed as they now know it is only a few short months until Afrezza will be on the market and they will have the opportunity to change their lives significantly for the better and perhaps extend them with a healthier longer and less degenerated physical situation if as we hope Afrezza ultimately is proved to stop the progression of the disease by lowering FGL's from 180 or so to 140 or perhaps 130... Might be a good time to watch the testimony of diabetics at Adcom again... to remind us of the potential for Afrezza... Also while approval may have been priced in and there is now some talk about technosphere in the "chatter" I really don't think any of that has been priced in. So with a good partnership deal we should see a "jump" but with the first announced technosphere deal we should see a "leap..." I remain convinced mnkd is a 3 to 5 year (IMHO) hold unless something extraordinarily negative comes from out of nowhere... And I will continue to accumulate where I can. Spent my wad on Friday's dip... so not today. The bears/shorts will not ruin my party... They have just put off my plans to buy my first Ferrari... and I can wait a few more months... GLTA! |
|
|
|
Post by jefferson on Jul 2, 2014 10:19:35 GMT -5
not sure at this point what the fear of anyone here would be? we've seen this a million times before, these hit pieces are just providing buying opportunities.
KEEP IN MIND: Mannkind hasn't even issued a press release yet... Something big is coming!!!
LOAD UP
|
|
|
|
Post by babaoriley on Jul 2, 2014 10:42:04 GMT -5
I must admit my confidence is shaken a bit by the stock drop. Simply put I expected FDA approval to really get the ball rolling for us. Not only in a price jump (14-15 pps) but I expected the "band wagon" investors to jump aboard. The negative articles are still coming with full guns blazing! I am long but am hopeful the "partnership" will be the key for us who believe in the product as well as want to make a few dollars. Partnership plus a good marketing strategy should be the key for us! Bradley, do not be shaken. This is typical, and is intended to have the exact effect it is having on many of us. They don't have multiple players looking at making a deal without cause. This is the short interest doing what it can to escape. And they do a great job of it; I'd almost congratulate them, but they have to skirt ethical conduct in order to pull this crap off, so I won't, other than to say, they know what they can get away with. When you consider the number of puts and calls which have been written on this stock, and the short stock position, there's a heck of a lot at stake, and people will do almost anything to win. It's not pretty and I'm not happy, but I have to accept it. What is more difficult to accept is my own shortcomings, as I saw this coming and did not act in a proper fashion; I closed out certain positions too early, when the stock was about 11, rather than waiting for this further pullback. Shorts are cold, they act our of self interest and don't scare. Most longs are more emotional; that's me, and I got caught up in the same thing you and many others did. And shorts know that these type of negative articles will scare people out of or away from the stock, because most investors are not as well informed as we are. We wait for the partnership, it should be a pretty good deal, notwithstanding that it will be slammed by the same ilk that are slamming us now. |
|
|
|
Post by kc on Jul 2, 2014 10:59:27 GMT -5
Just think long term. MNKD is on sale until the bell rings on Thursday's close. Market closes at 1:00 pm so you better buy on sale. How low will it be driven until some announcement ? Nobody knows. But the hard part was FDA approval.
Management is smart. They knew not to do much this week as it was has always been a dead week with the 4th of July. Do you want a premature announcement? I don't think so.
Remember the Technosphere slogan. YOUR DRUG, OUR DELIVERY. Besides Afrezza we have Technosphere. This image below gets me all excited about the potential of what the device offers other drugs. You can bet in a partnership or buyout that they will make sure the value is there for all concerned.
Go to your broker and be prepared to buy while on sale.
|
|
mnkdnyc
Lab Rat
Posts: 48
Sentiment: Long
|
Post by mnkdnyc on Jul 2, 2014 12:45:12 GMT -5
I just called fidelity about the short interest and mnkd is still very much in demand. That want to borrow your shares and still are paying 10% to do so. Just an fyi.
|
|
|
|
Post by slushy on Jul 2, 2014 12:50:16 GMT -5
I'm right there with you Baba... very disappointed in myself for pulling the trigger too soon on Monday when I fully expected the price to breakdown with the hit pieces and profit taking, especially on a short week like this. The good news is the articles at best hash up the old wounds of Exubera, and throw out the "MNKD is doomed without a partner" schtick. We could've picked up a point or two in SP for sure, but I'd rather be in a little too early than a little too late. The price is going to dance for a bit, but it's not going to take much to get the momentum to swing back in our direction. This is all a buying opportunity.
|
|
|
|
Post by savzak on Jul 2, 2014 13:15:18 GMT -5
I'm right there with you Baba... very disappointed in myself for pulling the trigger too soon on Monday when I fully expected the price to breakdown with the hit pieces and profit taking, especially on a short week like this. The good news is the articles at best hash up the old wounds of Exubera, and throw out the "MNKD is doomed without a partner" schtick. We could've picked up a point or two in SP for sure, but I'd rather be in a little too early than a little too late. The price is going to dance for a bit, but it's not going to take much to get the momentum to swing back in our direction. This is all a buying opportunity. Slushy, I'm so jaded to the term "buying opportunity" that I typically roll my eyes when I see a long investor mention it on one of the boards. But this time, I think you've hit the nail on the head using that term. Millions of shares of MNKD traded above $10 before approval. Approval with a solid label has removed the most serious single risk to MannKind's ultimate success. Yet here we are on the 3rd day after approval trading below $10 even though the entire market knows we're on the eve of a deal announcement.
Given Haken's time frame of 6 to 8 weeks, the market will be expecting an announcement by the end of August with a distinct possibility of an announcement by mid-August. And the market can't ignore the possibility that a deal might come even earlier. Given that, what do you think the chances are that the stock stays below $10 for more than a week or two? I think it is very likely that we'll be solidly over $10 by mid-July and over $11 by August 1.
If I were making any moves today, I would not be selling hoping for a lower buy in price. Everything about the current situation suggests an appreciating PPS very soon. I wouldn't want to be caught hoping for a lower price in the face of these factors. If I had powder left, I'd be a buyer today.
|
|
|
|
Post by mannmade on Jul 2, 2014 14:52:34 GMT -5
BTW, my broker platform called to say they would give me 11% if I agreed to loan my shares and that was after a 50/50 split which means thy are charging 22%...
|
|
|
|
Post by thekindaguyiyam on Jul 2, 2014 15:34:06 GMT -5
I'm right there with you Baba... very disappointed in myself for pulling the trigger too soon on Monday when I fully expected the price to breakdown with the hit pieces and profit taking, especially on a short week like this. The good news is the articles at best hash up the old wounds of Exubera, and throw out the "MNKD is doomed without a partner" schtick. We could've picked up a point or two in SP for sure, but I'd rather be in a little too early than a little too late. The price is going to dance for a bit, but it's not going to take much to get the momentum to swing back in our direction. This is all a buying opportunity. Slushy, I'm so jaded to the term "buying opportunity" that I typically roll my eyes when I see a long investor mention it on one of the boards. But this time, I think you've hit the nail on the head using that term. Millions of shares of MNKD traded above $10 before approval. Approval with a solid label has removed the most serious single risk to MannKind's ultimate success. Yet here we are on the 3rd day after approval trading below $10 even though the entire market knows we're on the eve of a deal announcement.
Given Haken's time frame of 6 to 8 weeks, the market will be expecting an announcement by the end of August with a distinct possibility of an announcement by mid-August. And the market can't ignore the possibility that a deal might come even earlier. Given that, what do you think the chances are that the stock stays below $10 for more than a week or two? I think it is very likely that we'll be solidly over $10 by mid-July and over $11 by August 1.
If I were making any moves today, I would not be selling hoping for a lower buy in price. Everything about the current situation suggests an appreciating PPS very soon. I wouldn't want to be caught hoping for a lower price in the face of these factors. If I had powder left, I'd be a buyer today.
thanks! Just what I needed to hear. I shifted upon the confirmation of my own thoughts with yours. Sold off other assets and acquired 61 call contracts that were a great value with a strike date of 1/2015. I was on the line thinking about taking the leap. Your comment cemented my own conviction. |
|
|
|
Post by 4allthemarbles on Jul 2, 2014 23:02:13 GMT -5
You know, sometimes this board has just the answers you need. in the darkest of (MNKD) days this board was a great resource. It still is. I am sooo dam LONG.
|
|
|
|
Post by ashiwi on Jul 3, 2014 4:53:14 GMT -5
Fidelity has upped the interest on my loaned shares to 12%. They are charging the borrowers 18%.
|
|
|
|
Post by mrhaigs on Jul 3, 2014 8:12:20 GMT -5
Fidelity has upped the interest on my loaned shares to 12%. They are charging the borrowers 18%. Can you remind me what it was before? I would think this may signal people to start covering? 18% is an insane interest rate. |
|
But this shall pass... None of the articles can say much about the science. Just the label. And Afrezza's HUGE benefits will be proved out as time goes by... Just as the negative jive talk will fade away as it is proved to be mostly untrue or statistically insignificant... 
